Skip to main content
OpenTrials
Completed

NCT Number: NCT04617197

Transcutaneous Electrical Nerve Stimulation With Frequency Specific Microcurrent Resonance Therapy for Non Specific Chronic Low Back Pain Patents: a Prospective Double Blinded, Randomized, Placebo Control Trial

Transcutaneous electrical nerve stimulation (TENS) is widely used for chronic pain. Recent studies showed frequency-specific microcurrent (FSM) resonant therapy was safe and effective in patients with non-specific chronic low back pain. However, there was no prospective, double-blinded randomized controlled trial to validate the clinical applicability. The goal of this trial is to verify safety and efficacy of FSM using a TENS device, Dragon Waves Resonant Home Care Electronic Nerve Stimulator-DW1330,(Taiwan Resonant Waves Research Co, Taiwan R.O.C), in 60 patients with non-specific low back pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Taipei Medical University

Taipei, Taiwan

About this study

Several studies showed that frequency-specific microcurrent (FSM) resonance therapy delivered by transcutaneous electrical nerve stimulation (TENS) device is safe and effective in patients with non-specific low back pain. The regiment of variable-frequency combination (1-10000 Hz or 1-20000 Hz), continuous use for 36-60 mins per day and 30 to 180 days per session has been proven to be safe. To validate the clinical applicability of FSM by using a TENS device, DW-1330 (Taiwan Resonant Waves Research Co., Taiwan R.O.C.), a prospective, randomized, double-blinded trial is proposed. Investigators are going to recruit 60 patients with non-specific low back pain for at least 3 months. Clinical assessments include Numerical Rating Scale (NRS), Oswestry Disability Index (ODI), EuroQol instrument (EQ-5D), Pressure pain threshold (PPT), and Heart rate variability (HRV). The 60 patients were double-blinded, 1:1:1-randomly-distributed into 3 groups using different variable-frequency combinations: (1) Variable-frequency combination 1 (2) Variable-frequency combination 2 (3) Control(Placebo). During the surveillance period, a total of 2 visits and a telephone follow-up is set at Time point = 0, 2(telephone) and 4 week after recruitment. The primary endpoint is the change of NRS. The secondary endpoint is change of Heart rate variability (HRV). The safety evaluated index is the adverse event rate for all 3 groups.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 20-80 years old, male or female.
  • Cases with normal psychological and communication functions who can cooperate with our study.
  • Cases who are willing to sign permits and cooperate with our study including follow up and examination.
  • Cases with complete clinical data and willing to accept investigation.

Exclusion criteria

  • Cases who diagnose pregnancy within 12 months before included.
  • Cases who diagnose with malignant disease.
  • Cases with a history of epilepsy.
  • Cases who diagnose with fracture without fixation.
  • Cases who diagnose with impaired sensation or psychological function.
  • Cases whose skin condition is not feasible to accept treatment.
  • Cases with pacemaker.
  • Cases who allergic to the conductive medium
  • Cases with a major psychiatric disorder such as schizophrenia or bipolar disorder.
  • Cases with severe visual or auditory disorder.
  • Cases who cannot communicate with the Mandarin language.
  • Other mental diseases are not suitable assessed by the PI

Treatment and study plan

Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy

Device

Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)

Primary outcomes

  1. Changes of non-specific chronic low back pain scaled by numerical rating scale

    Time frame: Time point = 0 week (before treatment), 2 week (during the treatment, by a telephone follow-up) and 4 week (after a 4-week treatment )

    In a Numerical Rating Scale (NRS), patients are asked to circle the number between 0 and 10, 0 and 20 or 0 and 100 that fits best to their pain intensity [1]. Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible'.

Secondary outcomes

  1. Changes of Heart rate variability

    Time frame: Time point = 0 week (before treatment) and 4 week (after a 4-week treatment )

    standard deviation of the normal-to-normal QRS interval (SDNN)

Other outcomes

  1. Adverse rate

    Time frame: Time period during 4-week treatment

    Any adverse event accompany with the treatment will be document

Sponsors and collaborators

Lead sponsor

Taipei Medical University

Other

Collaborators

  • Taiwan Resonant Waves Research Corp.

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Nov 5, 2020
Registry last updated
Apr 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.